Skip to main content

Table 4 On-treatment COPD-related medical costs for the UMEC/VI and TIO cohorts

From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

  UMEC/VI (N = 3929) TIO (N = 3929) Cost difference (95% CI) p value
On-treatment period, mean days (SD) [median] 203.0 (249.0) [90] 139.4 (197.9) [60]
COPD-related medical costs, $US 2019 PPPM, mean (SD)
 Total medical costs 867 (3259) 1095 (7958) − 228 (− 504, − 15) 0.028
 Hospitalizations 406 (1837) 461 (2414) − 54 (− 161, 49) 0.309
 ER visits 123 (2275) 125 (707) − 2 (− 38, 36) 0.914
 Outpatient visits 296 (1129) 462 (7433) − 166 (− 409, − 7) 0.036
 Other visits 41 (181) 48 (176) − 6 (− 15, 3) 0.184
  1. CI, confidence interval; COPD, chronic obstructive pulmonary disease; PPPM, per patient per month; SD, standard deviation; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol